San Diego, CA – Human Longevity, Inc. has expanded its commitment to cancer prevention by pledging $1 million to support early detection efforts for pancreatic cancer in eligible members.
According to the company, the funds will be used to provide up to $10,000 in reimbursable support per qualified member for diagnostic and follow-up testing. This offer is available to those participating in Human Longevity’s Health Nucleus program who meet the clinical eligibility requirements.
The company said that the pledge builds on its broader mission to use precision health technologies to improve early detection of diseases. The initiative is focused specifically on pancreatic cancer, which the company claims is difficult to detect in early stages but has significantly better outcomes when diagnosed early.
Human Longevity claims that this financial support aims to remove cost as a barrier to advanced screening, enabling proactive intervention in high-risk individuals. The pledge is positioned as part of the company’s strategy to extend healthspan through preventative care and data-driven insights.
The company said that details regarding program eligibility and reimbursement processes are available to existing members through its clinical team.
